临床试验/NCT01185717

NCT01185717已完成不适用

Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients

Biogen0 个研究点目标入组 7,726 人开始时间: 2010年9月最近更新: 2014年6月2日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Biogen
入组人数: 7,726
主要终点: Prevalence of anti-JCV antibodies

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

The objective of the study is to estimate the prevalence of anti-JCV antibodies in multiple sclerosis (MS) participants.

详细描述

This is a cross-sectional, multi-center, multi-national, epidemiological study to estimate the prevalence of anti-JCV antibody in MS participants. This study will provide an estimate of the prevalence of anti-JCV antibody in the MS population and will investigate inter-country differences.

研究设计

研究类型: Observational
时间视角: Cross Sectional

入排标准

性别: All
接受健康志愿者: 否

入选标准

•All candidates for this study must have the ability to understand the purpose of the study and provide signed and dated informed consent.
•All patients with a diagnosis of Multiple Sclerosis (MS) of any type, irrespective of their treatment, are eligible to participate once.

排除标准

•NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

结局指标

主要结局

Prevalence of anti-JCV antibodies

时间窗: Single timepoint (Day 1)

Prevalence of anti-JCV antibodies will be estimated as the number of participants with anti-JCV antibodies detected in serum divided by the total number of participants with a serum sample that was evaluated.

次要结局

未报告次要终点

研究者

发起方

Biogen

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

不适用

Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients: JEMSMultiple Sclerosis

NL-OMON34210Biogen190

已完成

不适用

JC-Virus (JCV) Antibody ProgramMultiple Sclerosis

NCT01070823Biogen1,096

已完成

不适用

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With NatalizumabRelapsing Multiple Sclerosis

NCT01070836Biogen35,895

Unknown

1 期

Infections and Autoimmunity: Autobodies Screening in Multiple SclerosisMultiple Sclerosis

NCT00230204Sheba Medical Center100

进行中（未招募）

4 期

Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasJapanese Encephalitis

NCT06678373Liaoning Chengda Biotechnology CO., LTD250